






Hospitalization Rates Are Highest in the First 5 Years of Systemic Sclerosis: Results From a Population-based Cohort (1980–2016)

Caitrin M. Coffey¹ , Avneek S. Sandhu², Cynthia S. Crowson³ , Sara J. Achenbach⁴, Eric L. Matteson³ , Thomas G. Osborn¹ , Kenneth J. Warrington¹ , and Ashima Makol¹ 

ABSTRACT. *Objective.* Few studies have estimated the healthcare resource usage of patients with systemic sclerosis (SSc). The purpose of this study was to compare hospitalization among incident cases of SSc vs age- and sex-matched comparators.

Methods. A retrospective, population-based cohort of patients with SSc in Olmsted County, Minnesota, from January 1, 1980, to December 31, 2016, was assembled. A 2:1 cohort of age- and sex-matched patients without SSc from the same population was randomly selected for comparison. All hospitalizations in the geographic area from January 1, 1987, to September 30, 2018, were obtained. Rates of hospitalization, lengths of stay, and readmissions were compared between groups.

Results. There were 76 incident SSc cases and 155 non-SSc comparators (mean age 56 ± 16 yrs at diagnosis/index, 91% female) included. Rates of hospitalization among cases and comparators were 31.9 and 17.9 per 100 person-years, respectively (rate ratio [RR] 1.78, 95% CI 1.52–2.08). Hospitalization rates were higher in patients with SSc than comparators during the first 5 years after SSc diagnosis (RR 2.16, 95% CI 1.70–2.74). This difference decreased over time and was no longer significant at ≥ 15 years after SSc incidence/index. Lengths of stay (median [IQR] 4 [2–6] vs 3 [2–6], $P = 0.52$) and readmission rates (25% vs 23%, $P = 0.51$) were similar between groups.

Conclusion. Patients with SSc were hospitalized more frequently than comparators, indicating high inpatient care needs in this population. Hospitalization rates were highest during the first 5 years following SSc diagnosis.

Key Indexing Terms: facilities and services utilization, hospitalization, systemic sclerosis

This study used the resources of the Rochester Epidemiology Project, which is supported by the National Institute on Aging of the National Institutes of Health (NIH) under Award Number R01AG034676. This study was also supported by the John M. Nasseff, Sr. Clinician Career Development Award in Rheumatology to AM and Mayo Clinic CTSA through grant number UL1TR002377 from the National Center for Advancing Translational Sciences (NCATS), one of the institutes of the NIH.

¹C.M. Coffey, MD, Instructor of Medicine, T.G. Osborn, MD, Professor of Medicine, K.J. Warrington, MD, Professor of Medicine, A. Makol, MD, Assistant Professor of Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota; ²A.S. Sandhu, MD, Resident Physician, Department of Internal Medicine, Kettering Medical Center, Kettering, Ohio; ³C.S. Crowson, PhD, Professor of Biostatistics and Medicine, E.L. Matteson, MD, Professor of Medicine, Division of Rheumatology, and Department of Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, Minnesota; ⁴S.J. Achenbach, MS, Stat Program Analyst II, Department of Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.

The authors declare no conflicts of interest.

Address correspondence to Dr. A. Makol, Consultant, Associate Professor of Medicine, Division of Rheumatology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA. Email: Makol.ashima@mayo.edu.

Full Release Article. For details see Reprints and Permissions at jrheum.org.

Accepted for publication November 5, 2020.

Systemic sclerosis (SSc) is a rare systemic inflammatory disease characterized by widespread fibrosis of the skin and internal organs, microvascular injury, and autoimmunity. SSc affects multiple organ systems and is associated with high morbidity and mortality, exceeding that of other rheumatic diseases¹ and of the general population.² Patients frequently develop internal organ complications from SSc, including digital ischemia, renal crisis, pulmonary arterial hypertension (PAH), progressive interstitial lung disease (ILD), cardiomyopathy, arrhythmias, gastrointestinal (GI) dysmotility, and pseudo-obstruction. While the large majority requires close outpatient follow-up, many SSc-related complications may require in-hospital care. Cardiopulmonary disease is the major driver of mortality in SSc.³

Given the severity and multisystem involvement of SSc, patients have tremendous healthcare needs in the inpatient and outpatient settings. Hospitalizations, medications, and outpatient appointments are reported to make up the bulk of medical costs for patients with SSc.⁴ A previous population-based study from the United States reported that patients with SSc are more frequently hospitalized than unaffected matched controls, with longer lengths of inpatient stay.⁵ Healthcare costs were also higher in patients with SSc than in controls, including

costs for inpatient care, which are estimated to make up 31% of total annual healthcare cost.⁵ Among US patients with SSc, hospitalization has been consistently reported as occurring more commonly in women than men, with hospitalization rates increasing with age in 1995, 2002–2003, and 2012–2013 US hospital cohorts.^{6,7,8} Presence of ILD has been associated with frequency of hospitalization in an Australian cohort of patients with SSc.⁹

The purpose of this study was to compare hospitalization rates between incident cases of SSc vs age- and sex-matched comparators without SSc in a geographically based US population over 36 years. To our knowledge, this is the most recent study of its kind to evaluate inpatient care utilization in a population-based, incident US population, allowing for assessment of trends over the course of disease in recent years. Case identification and data collection in this study were conducted by comprehensive individual medical record review, whereas the majority of similar studies have used insurance-based or code-based data that can be subject to many limitations.^{5,9} Indications for hospitalization, length of stay, and readmission rates were also examined.

METHODS

This study was approved by the Mayo Clinic and Olmsted Medical Center institutional review boards (17-005603 and 033-OMC-17, respectively). A retrospective, population-based cohort of physician-diagnosed patients with SSc in Olmsted County, Minnesota, from January 1, 1980, to December 31, 2016, was assembled. The need for informed consent was waived.

Patients. Patients were identified using the resources of the Rochester Epidemiology Project (REP), which allows for identification of nearly all clinically recognized cases of SSc due to complete access to inpatient and outpatient records from all healthcare facilities and providers in the geographic area.¹⁰ Medical records of patients with a diagnosis or suspicion of SSc were reviewed manually. Included patients were age \geq 18 years, diagnosed with incident SSc by a rheumatologist between January 1, 1980, and December 31, 2016. Patients who declined to authorize the use of their medical records for research purposes were not included.

Fulfillment of the 2013 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) classification criteria for SSc was ascertained. An index date was assigned corresponding to the date of clinical diagnosis of SSc, made by a physician, as documented in the medical record. A 2:1 cohort of age- and sex-matched non-SSc patients from the same population base was randomly selected for comparison. Both matched non-SSc patients were given the same index date as their comparator with SSc. Inclusion as a comparator required age within 3 years of the patient with SSc, same sex, and absence of SSc diagnosis. Comparators were also excluded if their medical records contained the diagnosis of another rheumatic condition, such as rheumatoid arthritis, systemic lupus erythematosus, systemic vasculitis, or others.

Data collection. A retrospective review of records was performed and data on demographics, disease characteristics, autoimmune serologies, diagnosis of limited vs diffuse SSc, organ system involvement both at diagnosis (\pm 12 mos) and at time of last follow-up, and treatments were abstracted. Charlson Comorbidity Index was used to assess baseline comorbidities prior to the index dates.¹¹ Inpatient hospitalization data were obtained from the electronic medical records beginning 12 months prior to the SSc incidence/index date.

All hospitalizations in the geographic area from January 1, 1987, to September 30, 2018, were obtained. Data on admission and discharge dates were retrieved electronically. Cases and comparators who died or emigrated from Olmsted County prior to 1987 were excluded from analysis. Primary

discharge diagnosis information was available for hospitalizations in 1995 to present, with primary diagnosis made by the healthcare provider(s) caring for the patient at the time of hospital stay. For analyses using primary discharge diagnoses, cases, and comparators who died or emigrated from Olmsted County prior to 1995 were excluded from analysis.

Primary discharge diagnoses were grouped based upon Clinical Classifications Software (CCS) for International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) and ICD-10-CM from the Healthcare Cost and Utilization Project,¹² which classifies diagnoses each into 1 of 18 chapters (categories). SSc is categorized in Chapter 13: “Diseases of the Musculoskeletal System and Connective Tissue.” Primary discharge diagnoses were also manually reviewed by a physician (CMC) to determine whether the primary diagnosis represented an infectious etiology, and whether or not the diagnosis was a direct consequence of SSc.

Readmission was defined as occurring within 30 days of a discharge. Readmissions were treated as unique hospitalizations for the purposes of comparing hospitalization rates between groups. Patients were followed from the latter of index date or January 1, 1987 (defined as baseline) until death, migration from the geographic area, or September 30, 2018.

Statistical analysis. Descriptive statistics (means, medians, percentages) were used to summarize the characteristics of patients with SSc and comparators. Chi-square and rank-sum tests were performed to compare the baseline characteristics between patients with SSc and comparators. Hospitalization rates of cases and comparators were analyzed using person-year (PY) methods and rate ratios (RRs). Poisson regression models with smoothing splines were used to examine trends over time to allow for nonlinear effects. Length of stay was analyzed using generalized linear models adjusted for age, sex, and calendar year, with random intercepts to account for multiple hospitalizations per patient. Analyses were performed using SAS version 9.4 (SAS Institute) and R 3.2.3 (R Foundation for Statistical Computing). A *P* value $<$ 0.05 was considered statistically significant for analyses.

RESULTS

The cohort included 76 patients with incident SSc and 155 comparators without SSc. Mean age of included subjects was 56 ± 16 years at diagnosis/index, and both groups were 91% female. Baseline characteristics are displayed in Table 1. Sixty-nine of 76 (91%) patients with SSc met ACR/EULAR 2013 classification criteria. Median length of follow-up from baseline date was 10.3 (IQR 4.0–17.1) years for patients with SSc and 12.7 (IQR 6.4–19.7) years for comparators. Only 5 of the 76 patients were diagnosed with SSc prior to January 1, 1987.

Hospitalization rates. Rates of hospitalization among cases and comparators were 31.9 and 17.9 per 100 PY, respectively (RR 1.78; 95% CI 1.52–2.08; Table 2). Hospitalization rates were significantly higher among patients with SSc than comparators. Both men (RR 4.33, 95% CI 2.58–7.60) and women (RR 1.63, 95% CI 1.38–1.92) with SSc had substantially higher hospitalization rates than comparators of the same sex. Among all age groups, patients with SSc aged 20–49 years (RR 2.54, 95% CI 1.73–3.75), 50–64 years (RR 2.29, 95% CI 1.70–3.09), and 65 years and older (RR 1.46, 95% CI 1.18–1.80) were hospitalized more frequently than their non-SSc counterparts. Rates of hospitalization increased with age in both groups of patients with SSc and non-SSc subjects (Table 2). Rates of hospitalization also increased among those with SSc in later calendar years (Table 2).

Hospitalization rates were higher in patients with SSc compared with non-SSc comparators during the first 5 years

Table 1. Baseline characteristics of patients with systemic sclerosis (SSc) and matched comparators without SSc.

	SSc, n = 76	Non-SSc, n = 155	P
Age at original index date, yrs, mean (SD)	56.4 (15.8)	56.1 (15.5)	0.92
Sex, female	69 (91)	141 (91)	0.96
Race/ethnicity, White	67 (88)	146 (95)	0.070
Length of follow-up, yrs, median (IQR) ^a	10.3 (4.0–17.1)	12.7 (6.4–19.7)	–
Smoking status at original index date			0.44
Never	40 (53)	83 (55)	
Former	24 (32)	38 (25)	
Current	11 (15)	30 (20)	
BMI at original index date, kg/m ² , mean (SD)	26.5 (6.0)	30.9 (19.4)	0.004
Fulfilled 2013 ACR/EULAR classification criteria	69 (91)	–	–
Skin involvement		–	–
Limited cutaneous	64 (84)		
Diffuse cutaneous	10 (13)		
Sine scleroderma	2 (3)		
Clinical features		–	–
Telangiectasias	37 (49)		
Calcinosis	18/74 (24)		
ILD	7 (9)		
PAH	6 (8)		
Renal crisis	6/72 (8)		
GI dysmotility	37/74 (50)		
Inflammatory arthritis	35/73 (48)		
Raynaud phenomenon	71 (93)		
Digital ulcers	15/31 (48)		
Positive ANA	69/74 (93)	–	–
Scl-70+	7/38 (18)	–	–
Anticentromere+	29/38 (76)	–	–
RNAPIII+	2/38 (5)	–	–

Values are expressed as n (%) or n/N (%) unless otherwise indicated. ^aLength of follow-up from baseline to last follow-up. ACR: American College of Rheumatology; ANA: antinuclear antibodies; EULAR: European League Against Rheumatism; GI: gastrointestinal; ILD: interstitial lung disease; PAH: pulmonary arterial hypertension; RNAPIII: RNA polymerase III.

following SSc diagnosis (RR 2.16, 95% CI 1.70–2.74). This difference decreased over time and was no longer significant for ≥ 15 years after SSc incidence/index (Figure 1).

Overall, the most common primary discharge diagnoses for hospitalizations among patients with SSc were categorized as diseases of the circulatory system (6.5 hospitalizations per 100 PY), respiratory system (5.1 per 100 PY), digestive system (4.8 per 100 PY), and musculoskeletal (MSK) system and connective tissue (3.6 per 100 PY), the latter category including a primary diagnosis of SSc (Table 2). Among those without SSc, most common primary discharge diagnoses for hospitalizations were categorized as diseases of the circulatory system (3.3 hospitalizations per 100 PY), respiratory system (2.0 per 100 PY), MSK system and connective tissue (2.0 per 100 PY), and injury or poisoning (2.0 per 100 PY; Table 2). Patients with SSc were more

frequently hospitalized for infections and diseases involving circulatory, digestive, and respiratory systems than comparators, with ratios ranging from 1.96 to 3.90 (Table 2).

Regardless of the CCS category in which primary discharge diagnosis was grouped, manual review demonstrated that 81 of 259 (31%) hospitalizations of patients with SSc with available discharge diagnosis information were due directly to underlying SSc. Sixty-four of the 259 (25%) hospitalizations in patients with SSc were related to infection. Of these hospitalizations, 37 of 64 (58%) involved patients with SSc on immunosuppressant medications.

Risk factor analysis. Analysis of risk factors for hospitalizations following SSc baseline date was performed, with adjustments made for age, sex, and calendar year. Presence of coronary artery disease (HR 1.64, 95% CI 1.01–2.64, $P = 0.04$), diabetes (HR 2.99, 95% CI 1.71–5.22, $P = 0.0001$), hypertension (HR 1.83, 95% CI 1.33–2.52, $P = 0.0002$), and PAH (HR 2.08, 95% CI 1.26–3.43, $P = 0.004$) was associated with higher risk of hospitalization. Patients with diffuse cutaneous vs limited cutaneous involvement or sine scleroderma were less likely to be hospitalized (HR 0.54, 95% CI 0.34–0.87, $P = 0.01$). Current (HR 1.15, 95% CI 0.80–1.66) or ever (HR 1.20, 95% CI 0.88–1.63) smoking, ILD (HR 1.84, 95% CI 0.86, 3.93), digital ulcers (HR 0.99, 95% CI 0.61–1.62), and SSc-specific antibodies such as anticentromere (HR 0.84, 95% CI 0.44–1.61), topoisomerase/Scl-70 (HR 0.98, 95% CI 0.49–1.96), and RNA polymerase III (RNAPIII; HR 2.23, 95% CI 0.92–5.44) did not have significant associations with hospitalization in this cohort.

Length of stay and readmission. Lengths of stay (median [IQR] 4 [2–6] vs 3 [2–6], $P = 0.52$) were similar among cases and comparators. There were comparable rates of readmission in the groups, with 55 readmissions among patients with SSc (25% of 219 subsequent hospitalizations) and 64 readmissions (23% of 283 subsequent hospitalizations) among comparators ($P = 0.51$).

DISCUSSION

This study reports hospitalization rates among 76 patients with incident SSc compared with age- and sex-matched comparators without SSc within the same geographic population in the US, with a median follow-up duration of 10.3 (IQR 4.0–17.1) years. SSc is a chronic condition affecting multiple organ systems and is associated with high morbidity and mortality. Not surprisingly, the rate of hospitalization of patients with SSc, at 31.9 hospitalizations per 100 PY, was significantly higher than comparators without SSc at 17.9 per 100 PY (Table 2). The increased rate of hospitalization observed in patients with SSc was seen in both sexes and in all age groups despite similar comorbidities, suggesting that the increased need for inpatient hospital care relates to the presence of SSc and its sequelae. Rates of readmission and lengths of stay did not differ between groups.

The findings of this study are consistent with prior research, showing that healthcare costs, inpatient care, and outpatient healthcare utilization are higher in patients with SSc than in those without SSc.⁵ Furst, *et al* demonstrated in 2012 that

Table 2. Hospitalization rates for patients with and comparators without systemic sclerosis (SSc), overall, and by sex, age, calendar year, and primary diagnosis.

	SSc Hospitalizations, Rate per 100 PY	Non-SSc Hospitalizations, Rate per 100 PY	RR (95% CI)
Overall	278 (31.9)	369 (17.9)	1.78 (1.52–2.08)
Sex			
Women	239 (29.4)	349 (18.1)	1.63 (1.38–1.92)
Men	39 (66.0)	20 (15.1)	4.33 (2.58–7.60)
Age, yrs			
20–49	55 (26.8)	48 (10.6)	2.54 (1.73–3.75)
50–64	86 (28.1)	87 (12.3)	2.29 (1.70–3.09)
65+	137 (37.9)	234 (26.0)	1.46 (1.18–1.80)
Calendar year			
1987–1996	30 (28.5)	49 (23.6)	1.21 (0.76–1.88)
1997–2006	83 (30.5)	115 (18.0)	1.70 (1.28–2.25)
2007–2018	165 (33.3)	205 (16.8)	1.98 (1.61–2.43)
Primary diagnosis			
Infection	10 (1.3)	6 (0.3)	3.90 (1.50–11.44)
Digestive	38 (4.8)	33 (1.7)	2.77 (1.74–4.43)
Respiratory	41 (5.1)	39 (2.0)	2.54 (1.64–3.94)
Circulatory	52 (6.5)	64 (3.3)	1.96 (1.35–2.82)
MSK ^a	29 (3.6)	39 (2.0)	1.80 (1.10–2.89)
Injury	26 (3.3)	38 (2.0)	1.66 (1.00–2.70)
Neoplasms	10 (1.3)	20 (1.0)	1.24 (0.55–2.53)
Mental illness	1 (0.1)	22 (1.1)	0.16 (0.01–0.55)

^aSSc diagnoses were classified under the MSK system by CCS (Chapter 13). CCS: Clinical Classifications Software; MSK: musculoskeletal; PY: person-year; RR: rate ratio; SSc: systemic sclerosis.




Figure 1. Age- and sex-adjusted hospitalization rates among patients with SSc (solid line) and non-SSc comparators (dashed line) according to disease duration. SSc: systemic sclerosis.

patients with SSc had a significantly higher rate of inpatient hospital stays, with 0.33 hospitalizations per patient per year compared with 0.09 for those without SSc in the same managed care network in the US.⁵ The rates of hospitalization from the Furst, *et al*⁶ study are similar to findings from the current study; this is despite differences in methodology, such as utilizing data from multiple geographic areas within a managed care organization, and including individuals with SSc based upon diagnosis

code at any phase of the disease process rather than incident SSc, as in the current study. In an international population of Australian patients with SSc, an average of 2.8 annual hospitalizations per patient without ILD and 3.9 per SSc patient with ILD were reported.⁹ Additionally, prior research has shown that hospitalization occurs more frequently in patients with other rheumatic conditions than the general population, including in giant cell arteritis,¹³ and sarcoidosis.¹⁴

In this study population, men with SSc had higher rates of hospitalization than both their male non-SSc comparators and women with SSc. Sex differences have previously been described in SSc, with women more frequently affected and at a younger age than men.¹⁵ However, men with SSc are more likely to have ILD, and have worse survival than women with SSc.¹⁵ While specific reasons for sex-related differences in hospitalization rates were not examined, we hypothesize that more severe disease and organ manifestations may underlie the increased rates of hospitalization observed in male patients. Prior studies have reported a predominance of female patients with SSc hospitalized in the US^{6,7,8}; however, this likely reflects the fact that females are more likely to be affected by SSc and comparing rates of hospitalization among all patients with SSc was not possible due to the methodology of these studies, using cross-sectional samples of hospitalization events rather than population-based cohorts.

The findings from the current study suggest that hospitalization rates are highest early in the course of SSc, with an RR of 2.16 for patients with SSc compared with comparators during the first 5 years after SSc diagnosis/index, a difference that decreased over time. This finding persisted after adjusting for patient age and sex. The higher hospitalization rates observed early in the disease process may parallel development of morbidity during the course of SSc, as a large majority of organ manifestations such as cardiac disease, ILD, and renal crisis occur during the first 5 years of disease onset. Alternatively, hospitalization may relate to symptoms that ultimately result in establishing a diagnosis of SSc; it may also result from early complications of SSc due to inadequate disease control or delayed initiation of treatment in the first 5 years of disease. Reasons for this difference were not specifically explored and will be an interesting topic for further study.

Previous research involving US-based patients with SSc has shown that these patients were most commonly hospitalized for diseases involving the circulatory, GI, MSK, and respiratory systems.^{7,8} In the most recent reports based upon data from the National Inpatient Survey, infection was the most common reason for hospitalization, representing 17.4% of all hospitalizations among patients with SSc in 2012–2013.⁸ Our findings were comparable with prior research, showing that diseases of the circulatory, digestive/GI, and respiratory systems were the most common primary reasons for hospitalization. However, when relying upon CCS codes, hospitalization for infection (Chapter 1, “Infectious and Parasitic Diseases”) occurred at a rate of only 1.3 hospitalizations per 100 PY, representing 3.9% of all hospitalization events in the SSc group during the study interval. Hospitalizations for infection by CCS Chapter 1 were nearly 4-fold more frequent in patients with SSc than in comparators. When a physician reviewed each hospitalization’s primary diagnosis individually, reclassifying diagnoses (e.g., from cellulitis to infection; CCS Chapter 12, “Diseases of Skin and Subcutaneous Tissue”), we observed that 25% of hospitalizations in patients with SSc were due to infectious causes. We postulate that the use of primary diagnosis coding, systematic assessment of multiple hospital diagnoses historically at the time of hospitalization, and underlying differences in study populations may

have contributed to the difference in results from those seen in prior research. We also note that due to this study’s population being geographically based, the severity of disease may be lower than those of other hospital-based or tertiary referral-based SSc populations, contributing to differences seen in the reasons for hospitalization.

Strengths of this study include a geographic, population-based cohort with 2 matched controls for each patient with SSc; data obtained from detailed, individual medical record review; and use of the REP, allowing comprehensive access to information about hospitalizations among all healthcare facilities in the geographic area regardless of insurance status or payer. Use of CCS for categorization of primary diagnoses during hospitalizations allowed for better comparison with prior studies.

A potential limitation of this study is its aforementioned reliance upon historical diagnosis codes and use of primary diagnosis coding. As SSc is a multisystem illness, hospitalization for multiple affected systems is not captured with the use of primary diagnosis only. The primary reason for hospitalization may have been categorized as SSc (Chapter 13) or affected organ (e.g., Chapter 8, “Diseases of the Respiratory System”); this was decided historically by the treating provider rather than a prospective protocol. This study was limited by small sample size despite a long study interval, and the fact that cost associated with hospitalizations was outside of the scope of this work, though it has been addressed in prior research. The matched design of this study may potentially allow for bias due to depletion of “susceptibles.” Additionally, this study was limited to residents of a particular geographic area in the Midwest US and the inpatient care needs of this population may not be generalizable to persons in other regions, nations, or healthcare systems.

Although there is a distinction between “classification” and “diagnosis,” the ACR/EULAR 2013 classification criteria are regarded as the most sensitive, particularly in early disease (in comparison to the 1987 ACR criteria); therefore, these criteria were evaluated in all patients diagnosed before and after their development in 2013 for the purposes of reporting in this study. There are limitations to using the 2013 classification criteria for this population, given that it is a cohort that started in 1980. For example, the RNAPIII autoantibody, which is now included in 2013 classification criteria, was not widely adopted until more recent years, and therefore not tested in many patients in this study. Likewise, formal video nailfold capillaroscopy was not available until recent years and abnormal nailfold capillaries as part of 2013 classification criteria may not be reported in the medical record in many cases in which bedside examination aided the rheumatologist’s diagnosis. Manifestations such as calcinosis, esophageal dysmotility, and inflammatory arthritis are not captured in the 2013 criteria, but may have contributed to clinical picture and eventual diagnosis of SSc in many of the patients included in this study.

In conclusion, this study demonstrates that patients with SSc are hospitalized more frequently than persons in the same geographic population without SSc. Rates of hospitalization were nearly 3-fold higher among male than female patients with SSc. Hospitalization of patients with SSc occurs more frequently

in the 5 years following diagnosis, and rates approach those of the non-SSc population over time. SSc places a large burden on patients and healthcare systems, and continued efforts are needed to reduce the disease burden and improve care for this group of patients.

REFERENCES

1. Denton CP, Khanna D. Systemic sclerosis. *Lancet* 2017; 390:1685-99.
2. Rubio-Rivas M, Royo C, Simeon CP, Corbella X, Fonollosa V. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. *Semin Arthritis Rheum* 2014;44:208-19.
3. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. *Ann Rheum Dis* 2010;69:1809-15.
4. Fischer A, Zimovetz E, Ling C, Esser D, Schoof N. Humanistic and cost burden of systemic sclerosis: a review of the literature. *Autoimmun Rev* 2017;16:1147-54.
5. Furst DE, Fernandes AW, Iorga SR, Greth W, Bancroft T. Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population. *J Rheumatol* 2012;39:2303-9.
6. Neitert PJ, Silverstein MD, Silver RM. Hospital admissions, length of stay, charges, and in-hospital death among patients with systemic sclerosis. *J Rheumatol* 2001;28:2031-7.
7. Chung L, Krishnan E, Chakravarty EF. Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample. *Rheumatology* 2007;46:1808-13.
8. Poudel DR, George M, Dhital R, Karmacharya P, Sandorfi N, Derk DT. Mortality, length of stay, and cost of hospitalization among patients with systemic sclerosis: results from the National Inpatient Sample. *Rheumatology* 2018;57:1611-22.
9. Morrisroe K, Stevens W, Sahhar J, Ngian JS, Ferdowski N, Hansen D, et al. The clinical and economic burden of systemic sclerosis related interstitial lung disease. *Rheumatology* 2020;59:1878-88.
10. Rocca WA, Yawn BP, St Sauver JL, Grossardt BR, Melton LJ. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. *Mayo Clin Proc* 2012;87:1202-13.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373-83.
12. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUP). [Internet. Accessed February 10, 2021.] Available from: www.hcup-us.ahrq.gov/home.jsp
13. Michet CJ III, Achenbach SJ, Crowson CS, Matteson EL. Hospitalization rates and utilization among patients with giant cell arteritis: a population-based study from 1987 to 2012. *Semin Arthritis Rheum* 2015;45:70-4.
14. Ungprasert P, Crowson CS, Achenbach SJ, Carmona EM, Matteson EL. Hospitalization among patients with sarcoidosis: a population-based cohort study 1987-2015. *Lung* 2017;195:411-8.
15. Peoples C, Medsger TA Jr, Rosario BL, Feghali-Bostwick CA. Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes. *J Scleroderma Relat Disord* 2016;1:177-240.